TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01592110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ZX003:risperidone-SABER and the DosePro System
Description: 50 mg risperidone-SABER administered as 0.5 mL via the DosePro Needle-Free Injection System

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone-SABER
Description: 50 mg of risperidone-SABER administered as a SC injection of 0.5 mL
Study: NCT03172494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin degludec/liraglutide
Description: Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin degludec
Description: Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks.
Study: NCT01592110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone-SABER
Description: 100 mg of risperidone-SABER administered as a SC injection of 1.0 mL
Study: NCT02084940

Intervention type: DRUG
Intervention: GnRH antagonist depot Degarelix
Description: Women receive 20 mg of Degarelix on the first day of menstrual cycle followed by a fixed dose of 225 IU of recombinant FSH on the second day until the day of ovulation triggering
Study: NCT02362256

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Study: NCT03000764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsies
Description: Biopsies (12 G) will be performed :~* in non-irradiated breast skin~* in irradiated breast skin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples
Description: blood samples are collected:~* 10 ml in EDTA tube~* 2,5 ml in PAXgene Blood RNA tube~* 4 ml in EDTA tube
Study: NCT01663883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercise
Description: use of a handgrip for 3x2 minutes
Study: NCT01325090

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: The pharmacist will fill syringes in tuberculins of 1 ml with injectable solution of sodium chloride of 0,9 %.
Study: NCT03228836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab (IBI308) 200mg IV Q3W
Study: NCT03756142

Intervention type: DIAGNOSTIC_TEST
Intervention: Motion Analysis
Description: Analysis of orthostatic posture, initiation of walking and walking by a motion analysis system

Intervention type: DIAGNOSTIC_TEST
Intervention: Motion Analysis
Description: Analysis of orthostatic posture, initiation of walking and walking by a motion analysis system
Study: NCT02961790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin Chloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin Chloride
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04461574

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Orcellex Brush
Description: Subjects will receive vaginal vault smear using both Orcellex Brush and Cervex Brush at the same follow-up visit, with order of smear taking decided by randomization.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervex Brush
Description: Subjects will receive vaginal vault smear using both Orcellex Brush and Cervex Brush at the same follow-up visit, with order of smear taking decided by randomization.
Study: NCT02387125

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMB305
Study: NCT06354452

Intervention type: OTHER
Intervention: Person-level linkage of the database looking for relationship with sepsis survival and previous intake of certain drug families and previous dependence on health services.
Description: A descriptive analysis of the baseline demographics, risk factors, health status, comorbidities, frailty, and previous dependence on health services of all patients admitted to hospitals in the region will be carried out.~Both the overall data of patients admitted to hospitals in any ward and those admitted to ICU will be analysed. The survival data of patients will be compared with their previous individual drug consumption, trying to find out the relationship between chronic consumption of certain families of drugs and inhospital survival to sepsis. In addition, drug dependence and dependence on health services of sepsis survivors will be studied in comparison with their situation prior to sepsis.
Study: NCT01728129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DANA Rapid
Description: The DANA Rapid is a neurocognitive test self-administered on a small handheld computer. The DANA Rapid subtests measure simple reaction time, procedural reaction time, and reaction time sensitivity.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DANA Rapid
Description: The DANA Rapid is a neurocognitive test self-administered on a small handheld computer. The DANA Rapid subtests measure simple reaction time, procedural reaction time, and reaction time sensitivity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MACE
Description: The MACE is currently the only standardized and Department of Defense-designated method for the initial evaluation of suspected concussion in military operational settings. The MACE documents the history of the injury-causing incident; assesses cognitive deficits in orientation, immediate memory, concentration, and delayed recalls; and involves a neurological screening by a clinician.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MACE
Description: The MACE is currently the only standardized and Department of Defense-designated method for the initial evaluation of suspected concussion in military operational settings. The MACE documents the history of the injury-causing incident; assesses cognitive deficits in orientation, immediate memory, concentration, and delayed recalls; and involves a neurological screening by a clinician.
Study: NCT02074787

Intervention type: DEVICE
Intervention: Thermography
Description: Standard thermographic images

Intervention type: DEVICE
Intervention: Laser Doppler
Description: standard laser doppler analysis

Intervention type: DEVICE
Intervention: Spectrophotometric Intracutaneous analysis
Description: standard SIA scope imaging
Study: NCT00893009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline
Description: 100 mg twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01894854

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stem collar
Description: The stem has two versions, one with and one without a collar. The classical Furlong HAC had a collar.
Study: NCT01657279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical scenarios
Description: Clinicians will be randomized to a sequence of 5 clinical scenarios with a variable range of expected outcome \[i.e. from low (\<10%) to high (\>50%) expected risk death at 30 days\].
Study: NCT02566083

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-toric intraocular lens
Description: TECNIS One-piece Monofocal Model ZCB00

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: toric intraocular lens
Description: TECNIS One-piece Toric Models ZCT300 or ZCT400
Study: NCT01882621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monosialoganglioside(GM1)
Description: 80mg,ivdrip (in the vein) on day 0 - day 3 of each 21 day cycle. Number of Cycles: 4-6 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 80mg,ivdrip(in the vein) on day 0-3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
Study: NCT04329169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Implant Planning
Description: According to the virtual implant plan, a CAD/CAM tooth supported surgical guide will be fabricated to place the dental implant with a fully guided surgical protocol.The surgical guide will be manufactured from a photopolymer resin using a 3D printing machine. A hex- shaped metal sleeve will be inserted in the surgical guide with the flat surface located buccally so that it will help in orientation of the implant hex during the implant placement.
Study: NCT02387125

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronomic CPA
Study: NCT00668694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulation
Description: Stimulation given to the child by mother
Study: NCT02273635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andrographolides
Description: 140 mg andrographolides coated tablets twice a day orally administered for 24 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 140 mg excipients coated tablets twice a day orally administered for 24 months
Study: NCT01905722

Intervention type: OTHER
Group type: OTHER
Intervention: 3 Tesla
Description: 3 Tesla scanning with intravenous infusion of tracers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7 Tesla
Description: 7 Tesla scanning with intravenous infusion of tracers
Study: NCT01724086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC647055
Description: Type=exact number, unit=mg, number=150, form=capsule, route=oral. 3 or 4 capsules of 150 mg will be administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC647055
Description: Type=exact number, unit=mg, number=150, form=capsule, route=oral. 3 or 4 capsules of 150 mg will be administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC647055
Description: Type=exact number, unit=mg, number=150, form=capsule, route=oral. 3 or 4 capsules of 150 mg will be administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC647055
Description: Type=exact number, unit=mg, number=150, form=capsule, route=oral. 3 or 4 capsules of 150 mg will be administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC647055
Description: Type=exact number, unit=mg, number=150, form=capsule, route=oral. 3 or 4 capsules of 150 mg will be administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC647055
Description: Type=exact number, unit=mg, number=150, form=capsule, route=oral. 3 or 4 capsules of 150 mg will be administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC647055
Description: Type=exact number, unit=mg, number=150, form=capsule, route=oral. 3 or 4 capsules of 150 mg will be administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: Type=exact number, unit=mg, number=75, form=capsule, route=oral. 1 capsule of 75 mg will be administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: Type=exact number, unit=mg, number=75, form=capsule, route=oral. 1 capsule of 75 mg will be administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: Type=exact number, unit=mg, number=75, form=capsule, route=oral. 1 capsule of 75 mg will be administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: Type=exact number, unit=mg, number=75, form=capsule, route=oral. 1 capsule of 75 mg will be administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: Type=exact number, unit=mg, number=75, form=capsule, route=oral. 1 capsule of 75 mg will be administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: Type=exact number, unit=mg, number=75, form=capsule, route=oral. 1 capsule of 75 mg will be administered once daily.
Study: NCT00645879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ornithine alpha ketoglutarate
Description: A dose of 400 mg/kg up to 16 g per day was selected. Split into 2 doses taken for 4 weeks. If determined the drug with the best effect, drug will be taken for 30 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glutamine
Description: A dose of 400 mg/kg up to 16 g per day was selected. Split into 2 doses taken for 4 weeks. If determined the drug with the best effects, drug will be taken for 30 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: disodium citrate
Description: Dose: 7.5 mEq/Kg or 658 mg/kg up to 16 g per day Split into 2 doses taken for 4 weeks. If determined the drug with the best effects, drug will be taken for 30 weeks.
Study: NCT01533090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol (PEG)
Description: SELG-ESSE 1000 4 L: 2L THE DAY BEFORE OF COLONOSCOPY AND 2 L THE SAME DAY OF COLONOSCOPY

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG low volume with bisacodyl
Description: Lovolesse + Lovoldyl 2L of Lovolesse with 2 or 3 tablets of bisacodyl the day before of colonoscopy or 2L of Lovolesse with 2 or 3 tablets of bisacodyl the same day of colonoscopy
Study: NCT01682759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Omarigliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride (1 mg and/or 2 mg tablets). During the 54-week double-blind treatment period, glimepiride can be up-titrated, as appropriate, to a maximum total daily dose of 6 mg/day. Throughout the trial, down-titration of glimepiride may also occur based upon the participant's glucose measurements and clinical symptoms of hypoglycemia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Participants will continue on their stable dose (\>=1500 mg/day) of open-label metformin throughout the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will continue on their stable dose (\>=1500 mg/day) of open-label metformin throughout the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Insulin glargine can be used for rescue therapy, if glycemic control is not maintained. Insulin therapy should be initiated as per local country insulin glargine label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Insulin glargine can be used for rescue therapy, if glycemic control is not maintained. Insulin therapy should be initiated as per local country insulin glargine label.
Study: NCT03919760

Intervention type: BEHAVIORAL
Intervention: NAVIGATE
Description: NAVIGATE was developed in consultation with clinical and research experts, biostatisticians, health economists, consumers, family members, advocacy groups, and government officials. It is a form of coordinated specialty care for first episode psychosis consisting of 4 key intervention components:~1. individualized medication management using a decision support tool;~2. a package of psychoeducation and a blend of evidence-based psychotherapies called individual resiliency training (IRT);~3. supported employment and education (SEE);~4. a family education program
Study: NCT03086954

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)
Description: This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
Study: NCT00598078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate
Description: Dose 1
Study: NCT01724086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: Type=exact number, unit=mg, number=75, form=capsule, route=oral. 1 capsule of 75 mg will be administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Type=exact number, unit=mg, number=30 or 50, form=tablet or solution, route=oral. 0.375 mL or 0.625 ml (80 mg/mL) solution will be administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Type=exact number, unit=mg, number=30 or 50, form=tablet or solution, route=oral. 0.375 mL or 0.625 ml (80 mg/mL) solution will be administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Type=exact number, unit=mg, number=30 or 50, form=tablet or solution, route=oral. 0.375 mL or 0.625 ml (80 mg/mL) solution will be administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Type=exact number, unit=mg, number=30 or 50, form=tablet or solution, route=oral. 0.375 mL or 0.625 ml (80 mg/mL) solution will be administered once daily.
Study: NCT00598078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate
Description: Dose 2

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose 3
Study: NCT01724086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Type=exact number, unit=mg, number=30 or 50, form=tablet or solution, route=oral. 0.375 mL or 0.625 ml (80 mg/mL) solution will be administered once daily.
Study: NCT01749865

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-Induced Killer Cells
Description: Cytokine-Induced Killer Cells treatment for 4 cycles
Study: NCT03093974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMS
Description: 1 MIU equivalent to 80 mg colistimethate sodium diluted in 1 mL saline solution 0.45%. Investigational Medicinal Product (IMP) glass vials were shrink wrapped in opaque white plastic and provided in boxes of 30 vials (two weeks of b.i.d dosing).~The 1 MIU/mL CMS/0.45% saline solution was transferred from the glass vial into a specific nebuliser system fitted with a 0.3 mL medication chamber, for administration by inhalation. This delivered a nominal dose of 0.3 MIU/24 mg CMS (\~10 mg CBA) from the device.~The first dose of the IMP was administered at the site under the supervision of the site staff and subjects were instructed how to prepare and self-administer the IMP at home via a specific nebuliser system, b.i.d (morning and evening) over a period of 12 months.~At least 10 minutes (min) before each administration, an inhaled short-acting bronchodilator (e.g., salbutamol /albuterol), supplied by the Sponsor, could be taken to improve tolerability.
Study: NCT01681537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study: NCT02943863

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFNC followed by conventional nasal cannula

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional nasal cannula followed by HFNC
Study: NCT02271620

Intervention type: PROCEDURE
Group type: OTHER
Intervention: nasal allergen provocation test
Description: nasal allergen provocation test
Study: NCT03686579

Intervention type: RADIATION
Intervention: chest trauma
Description: clinical and radiological study
Study: NCT03335488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAVICTI
Description: RAVICTI, Oral Liquid Product 17.5 mL maximum total daily dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaPBA
Description: * NaPBA in patients weighing \< 20 Kg - 600 mg/Kg, maximum total daily dose~* NaPBA in patients weighing \> 20 Kg - 13 g/m2, maximum total daily dose
Study: NCT00739440

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: serum antiscorpion
Description: The dose may be required for the patient according to clinical manifestations and evolution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: serum antiscorpion
Description: The dose may be required for the patient according to clinical manifestations and evolution
Study: NCT03484052

Intervention type: OTHER
Group type: OTHER
Intervention: Jugular ultrasound
Description: Performing a jugular ultrasound by 2 operators before and after transfusion
Study: NCT00498927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Study: NCT02303730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: The starting dose of exenatide is 5 ug bid, subcutaneously, for 4 weeks, followed by 10 ug bid, subcutaneously, for 20 weeks. If hypoglycaemia (blood glucose\<2.9 mmol/l or \< 3.9 mmol/l at least 2 times) or serious intolerance occurs, the dose will be adjusted to 5 ug bid, subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: The starting dose of insulin glargine will depend upon the HbA1c level at screening(HbA1c \<8% use 0.1 -0.2 U/kg per day;HbA1c \>8% use 0.2 -0.3 U/kg per day).~Dose adjustment protocol for insulin glargine (at least 3 determinations of fasting blood glucose per week):~fasting blood glucose(FBG) \> 180 mg/dL(10 mmol/l): add 4 U; FBG 140-180 mg/dL(7.8-10 mmol/l): add 2 U; FBG 126-139 mg/dL(7.0-7.8 mmol/l): add 1 U.~If hypoglycemia, reduce insulin glargine by:~blood glucose \<70mg/dl（3.9mmol/l）: 10%-20%; blood glucose \<40mg/dl（2.2mmol/l）: 20%-40%.